Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
Cytokinetics (Nasdaq: CYTK) opened its annual Corporate Giving Program, inviting proposals from eligible U.S. non-profit 501(c)(3) organizations for 2026 grants.
The program offers donations up to $20,000 per organization, focusing on cardiovascular health equity, science education, and essential services in the Bay Area and Greater Philadelphia. Application deadline is August 3, 2026.
Cytokinetics (Nasdaq: CYTK) launched MYQORZO (aficamten) in Germany, its first commercial market in the European Union, for adults with symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM). This follows European Commission approval in February 2026, based on the Phase 3 SEQUOIA-HCM trial.
According to Cytokinetics, MYQORZO significantly improved exercise capacity, increasing peak oxygen uptake by 1.76 mL/kg/min versus 0.0 with placebo, and met all 10 prespecified secondary endpoints with statistically significant, clinically meaningful benefits. MYQORZO had prior approvals in the United States (December 2025) and China.
Cytokinetics (Nasdaq: CYTK) announced that management will participate in two June 2026 investor conferences. These include fireside chats at the Jefferies Global Healthcare Conference on June 3 in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 in Miami Beach.
Live webcasts and 90-day replays will be available via the company’s Investors & Media website.
Cytokinetics (Nasdaq: CYTK) will hold its Annual Meeting of Stockholders on May 27, 2026 at 10:00 AM PT at its headquarters, 350 Oyster Point Blvd., South San Francisco, CA.
Stockholders of record on March 31, 2026 may vote in person or by proxy. A live and archived webcast will be available for 12 months.
Cytokinetics (Nasdaq: CYTK) granted equity awards on May 15, 2026 as material inducements to 8 new employees under Nasdaq Listing Rule 5635(c)(4).
- 20,807 stock options at a $75.85 exercise price, 10-year term, vesting over 4 years
- 13,793 RSUs vesting over 3 years
Cytokinetics (Nasdaq: CYTK) will host the third annual Contemporary Landscapes in Muscle Biology (CLIMB) symposium on May 29, 2026, from 8:00 AM to 5:00 PM PT at the Mission Bay Conference Center in San Francisco.
Registration is free but capacity-limited, with an online deadline of May 22, 2026. CLIMB 2026 features a keynote by James A. Spudich, PhD, and expert sessions on cardiac biology, skeletal muscle biology and emerging treatment modalities, including genetic medicines, RNA medicines and muscle preservation.
Cytokinetics (Nasdaq: CYTK) announced participation in the 2026 RBC Capital Markets Global Healthcare Conference. Company management will join a fireside chat on May 19, 2026 at 3:35 PM ET in New York.
A live webcast and 90-day replay will be available via the Cytokinetics Investors & Media website.
Cytokinetics (Nasdaq: CYTK) reported new MYQORZO (aficamten) data at ESC Heart Failure 2026 from Phase 3 SEQUOIA-HCM, MAPLE-HCM and FOREST-HCM, plus real-world studies.
Results describe improved exercise capacity vs metoprolol, favorable left atrial remodeling, and long-term safety with stable arrhythmia rates and durable LVOT gradient and biomarker reductions.
Cytokinetics (Nasdaq: CYTK) closed an underwritten public offering on May 8, 2026, selling 11,338,028 common shares (including full exercise of a 1,478,873-share option) at $71.00 per share for gross proceeds of approximately $805 million.
All shares were sold by Cytokinetics; gross proceeds are before underwriting discounts, commissions and offering expenses.
Cytokinetics (Nasdaq: CYTK) priced an underwritten public offering of 9,859,155 common shares at $71.00 per share, raising approximately $700 million in gross proceeds before fees. The offering is expected to close on May 8, 2026 and includes a 30‑day option to sell 1,478,873 additional shares.
All shares are being sold by Cytokinetics; joint book‑running managers include Morgan Stanley, Goldman Sachs, J.P. Morgan and Jefferies. The offering is made under a shelf registration effective February 27, 2025.